title: Early detection of rejection and assessment of cyclosporine therapy by 111In antimyosin imaging in mouse heart allografts.
abstract: BACKGROUND. Mice (n = 58) with abdominal heterotopic heart transplants were studied to examine the effectiveness of 111In-labeled antimyosin scintigraphy in the detection of rejection and to determine the consequence of cyclosporine therapy on the results. METHODS AND RESULTS. Allografts from B10D2 donors were transplanted into B6AF1 recipients. Of the 49 allografted mice, 19 were treated with cyclosporine (15 mg/kg.day). Nine isografted mice served as controls. Scintigraphy was performed by injecting 100 muCi 111In antimyosin monoclonal antibody 2-15 days after transplantation. An increase in the ratio of percent dose of antimyosin injected per gram (% dose/g) of the grafted heart (G) to that of the autologous heart (A) (G/A) as well as the increasing percent dose per gram of antimyosin in the grafts reflected the severity of histopathological rejection regardless of the presence or absence of cyclosporine. Scintigraphic images demonstrated unequivocally intense accumulation of 111In in rejected allografts as confirmed by histologically demonstrable myocyte necrosis. The G/A ratio in allografted mice with mildly deteriorated mechanical activity (4.2 +/- 1.0, mean +/- SD) was greater than that in mice with normal contractility (1.8 +/- 0.7) (p less than 0.001), and the necrosis correlated with this modest decline in mechanical function could be scintigraphically identified. Of mice with normally contracting allografts, the G/A ratio was greater in animals with demonstrated myocyte necrosis (2.6 +/- 0.5) than in those without necrosis (1.5 +/- 0.5) (p less than 0.001). In contrast, isografted mice or a subset of allografted mice treated with cyclosporine and not showing evidence of rejection did not manifest any significant change in G/A ratio, nor did they have scintigrams positive for rejection as late as 15 days after transplantation. CONCLUSIONS. These findings suggest that antimyosin scintigraphy is a sensitive and early indicator of cardiac transplant rejection and that it could be useful as a noninvasive method for assessing the efficacy of cyclosporine treatment.
authors.affiliation: Cardiac Unit, Massachusetts General Hospital, Boston 02114.
authors.forename: M
authors.initials: M
authors.lastname: Isobe
authors.forename: E
authors.initials: E
authors.lastname: Haber
authors.forename: B A
authors.initials: BA
authors.lastname: Khaw
mesh_terms: D000005:Abdomen; D000818:Animals; D000911:Antibodies, Monoclonal; D003524:Cyclosporins / Q000627:therapeutic use*; D006084:Graft Rejection; D006321:Heart / Q000000981:diagnostic imaging*; D016027:Heart Transplantation / Q000276:immunology*; D007165:Immunosuppression Therapy; D007205:Indium Radioisotopes; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009218:Myosins / Q000276:immunology; D009942:Organometallic Compounds; D011877:Radionuclide Imaging; D013997:Time Factors; D016042:Transplantation, Heterotopic
chemical_list: D000911:Antibodies, Monoclonal; D003524:Cyclosporins; D007205:Indium Radioisotopes; D009942:Organometallic Compounds; C058899:imciromab pentetate; D009218:Myosins